{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:49Z","timestamp":1789972129506,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.bone.2011.02.011","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T05:03:39Z","timestamp":1298437419000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["Bisphosphonates for postmenopausal osteoporosis"],"prefix":"10.1016","volume":"49","author":[{"given":"Richard","family":"Eastell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Siris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2011.02.011_bb0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/cpt1976205593","article-title":"Etidronate disordium in postmenopausal osteoporosis","volume":"20","author":"Heaney","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bone.2011.02.011_bb0010","series-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","first-page":"259","article-title":"Pathogenesis of postmenopausal osteoporosis","author":"Eastell","year":"2006"},{"key":"10.1016\/j.bone.2011.02.011_bb0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/jbmr.5650110203","article-title":"A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates","volume":"11","author":"Parfitt","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0020","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(02)08706-8","article-title":"Pathogenesis of bone fragility in women and men","volume":"359","author":"Seeman","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2011.02.011_bb0025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S8756-3282(00)00318-5","article-title":"A novel mechanism for induction of increased cortical porosity in cases of intracapsular hip fracture","volume":"27","author":"Bell","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.02.011_bb0030","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2011.02.011_bb0035","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.02.011_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure","volume":"23","author":"Recker","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0045","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.090315","article-title":"Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"24","author":"Recker","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0050","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","article-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density","volume":"40","author":"Saag","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.02.011_bb0055","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clinthera.2009.04.018","article-title":"Efficacy and tolerability of once-monthly oral ibandronate (150mg) and once-weekly oral alendronate (70mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study","volume":"31","author":"Emkey","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.bone.2011.02.011_bb0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0065","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","article-title":"Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study","volume":"24","author":"Miller","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bone.2011.02.011_bb0075","first-page":"1895","article-title":"Reginster JY: risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0085","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thiebaud","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0090","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0095","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2011.02.011_bb0100","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2011.02.011_bb0105","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0110","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2011.02.011_bb0115","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","article-title":"Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women","volume":"103","author":"Stock","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0130","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0135","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1185\/030079904125004475","article-title":"Bone safety of long-term bisphosphonate treatment","volume":"20","author":"Rodan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bone.2011.02.011_bb0140","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.02.011_bb0150","first-page":"S22","article-title":"The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)","author":"Black","year":"2010"},{"key":"10.1016\/j.bone.2011.02.011_bb0155","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0160","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.02.011_bb0165","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0170","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0175","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0180","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0185","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0190","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0195","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1-34)rhPTH] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0205","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0210","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4065\/80.3.343","article-title":"Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of \u22121.6 to \u22122.5 at the femoral neck: the Fracture Intervention Trial","volume":"80","author":"Quandt","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bone.2011.02.011_bb0220","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-007-0493-y","article-title":"Effects of risedronate on fracture risk in postmenopausal women with osteopenia","volume":"19","author":"Siris","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.02.011_bb0225","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2008-2765","article-title":"Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0230","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","article-title":"Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study","volume":"20","author":"McCloskey","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.02.011_bb0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF02405341","article-title":"Preliminary observations of a form of coherence therapy for osteoporosis","volume":"36","author":"Anderson","year":"1984","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2011.02.011_bb0240","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N Eng J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0250","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/0378-5122(96)01018-3","article-title":"Clodronate and osteoporosis","volume":"23","author":"Kanis","year":"1996","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2011.02.011_bb0255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","article-title":"Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study","volume":"22","author":"McCloskey","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0260","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(89)92927-9","article-title":"Prevention of postmenopausal bone loss by tiludronate","author":"Reginster","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2011.02.011_bb0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s001980170126","article-title":"Intermittent cyclic tiludronate in the treatment of osteoporosis","volume":"12","author":"Reginster","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.02.011_bb0270","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0378-5122(96)01118-8","article-title":"Cyclical pamidronate infusions in postmenopausal osteoporosis","volume":"25","author":"Peretz","year":"1996","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2011.02.011_bb0275","first-page":"1399","article-title":"The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women","volume":"76","author":"Harris","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0280","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.02.011_bb0285","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2011.02.011_bb0290","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.02.011_bb0295","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0300","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.02.011_bb0305","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.02.011_bb0310","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0315","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.02.011_bb0320","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2011.02.011_bb0325","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0330","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1359\/jbmr.1999.14.4.602","article-title":"Monitoring alendronate therapy for osteoporosis","volume":"14","author":"Braga de Castro","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0335","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bone.2003.04.002","article-title":"Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption","volume":"34","author":"Hannon","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.02.011_bb0340","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.02.011_bb0345","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas","year":"2009","journal-title":"J Bone Miner Res"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211000639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211000639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:37:13Z","timestamp":1762659433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328211000639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S8756328211000639"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2011.02.011","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates for postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2011.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}